Evaluation of Pain With Radiesse® With Lidocaine for Nasolabial Folds

NCT ID: NCT01069354

Last Updated: 2018-05-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

102 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-11-30

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess pain during nasolabial fold treatment using Radiesse® Injectable Dermal Filler with lidocaine

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To assess pain immediately after nasolabial fold treatment with Radiesse® Injectable Dermal Filler with lidocaine in one nasolabial fold compared to Radiesse® Injectable Dermal Filler without lidocaine in the contralateral nasolabial fold

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nasolabial Folds

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Radiesse® Mixed with Lidocaine

Injectable Dermal Filler. The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).

Group Type EXPERIMENTAL

Radiesse® Injectable Dermal Filler with Lidocaine

Intervention Type DEVICE

Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier with 3% lidocaine hydrochloride (HCl)

Radiesse® without Lidocaine

Injectable Dermal Filler. The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).

Group Type ACTIVE_COMPARATOR

Radiesse® Injectable Dermal Filler without Lidocaine

Intervention Type DEVICE

Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier without 3% lidocaine hydrochloride (HCl)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Radiesse® Injectable Dermal Filler with Lidocaine

Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier with 3% lidocaine hydrochloride (HCl)

Intervention Type DEVICE

Radiesse® Injectable Dermal Filler without Lidocaine

Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier without 3% lidocaine hydrochloride (HCl)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Is at least 18 years of age
* Is a candidate for nasolabial fold treatment using Radiesse
* Has approximately symmetrical nasolabial folds
* Understands and accepts the obligation not to receive any other facial procedures in the lower half of the face for 1 month

Exclusion Criteria

* Has received any type of treatment or procedures including surgery in the nasolabial folds
* Has received neurotoxin, hyaluronic acid, calcium hydroxylapatite (CaHA) or collagen injections in the lower half of the face within past 6 months
* Has received polylactic acid, polymethyl methacrylate (PMMA), silicone or any other permanent filler in the lower half of the face
* Has nasolabial folds that are too severe to be corrected in one treatment session
* Has any history of hypersensitivity to lidocaine or anesthetics of the amide type
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Merz North America, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fred Derosier, DO

Role: STUDY_DIRECTOR

Merz North America, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Toronto, , Canada

Site Status

Woodbridge, , Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

References

Explore related publications, articles, or registry entries linked to this study.

Schachter D, Bertucci V, Solish N. Calcium Hydroxylapatite With Integral Lidocaine Provides Improved Pain Control for the Correction of Nasolabial Folds. J Drugs Dermatol. 2016 Aug 1;15(8):1005-10.

Reference Type RESULT
PMID: 27538003 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P120677

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Injectable Filler for Cheek Flattening
NCT01225354 COMPLETED PHASE4